![]() This pilot investigation lends baseline insight as to methylphenidate's potential in both reducing and exacerbating DPDR symptomatology for a subset of individuals, and underscores the need to examine its potential utility in treating DPDR in a larger and more controlled setting. These results highlight the potentially distinct subtypes of individuals with DPDR symptoms, and how they may respond differently to stimulant medication. There was also a significant three-way interaction between ADHD scores, DPDR scores, and methylphenidate ingestion, such that for control participants, DPDR symptoms decreased slightly over time regardless of ADHD symptom severity, whereas for treatment participants, DPDR symptoms increased much more over time the higher the level of ADHD symptoms the participant endorsed. Depersonalisation disorder involves an unpleasant, chronic and disabling alteration in the experience of self and environment. There was a significant three-way interaction between STAI-T scores, CDS scores, and methylphenidate ingestion, such that for control participants, DPDR symptoms decreased slightly over time regardless of trait anxiety, whereas for treatment participants, DPDR symptoms increased much more over time the higher the level of trait anxiety the participant reported. Control participants Saw marginal decreases in DPDR symptoms from baseline to two hours later, suggesting a non-significant decrease in symptoms possibly due to diurnal rhythms. In the treatment condition, DPDR scores increased if more time had elapsed between T1 and T2 whereas in the control condition, DPDR scores decreased if more time had elapsed. Results revealed marginally significant associations between methylphenidate and DPDR symptom changes over time at high levels of elapsed time between T1 and T2, and significant associations when trait anxiety and ADHD were included as moderators. Participants in the control condition took surveys at the same times. ![]() ![]() Participants in the treatment condition completed questionnaires assessing DPDR, anxiety, and ADHD symptoms prior to taking methylphenidate and approximately two hours post-ingestion, at peak medication concentration. Any withdrawal symptoms you experience may be treated with medication to ensure. A sample of 26 participants (8 = "treatment" and 18 = controls) were recruited on the basis of either taking methylphenidate as prescribed for attention-deficit hyperactivity disorder (ADHD) or their endorsement of ADHD while not taking methylphenidate or any other central nervous system stimulant medication. Derealization is when events that occur around you do not feel real. ![]() The present quasi-experimental study investigated the potential efficacy of stimulant medication methylphenidate (trade name: Ritalin) in reducing depersonalization/derealization disorder (DPDR) symptoms among a pilot sample of adult individuals (84.6% white, 7.7% black, 3.8% Hispanic, and 3.8% Asian 50% female) recruited from TurkPrime, a crowdsourcing Internet marketplace. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |